Litigation Details for FRESENIUS KABI USA LLC v. BIOQ PHARMA INC. (D.N.J. 2018)
✉ Email this page to a colleague
FRESENIUS KABI USA LLC v. BIOQ PHARMA INC. (D.N.J. 2018)
Docket | ⤷ Try a Trial | Date Filed | 2018-02-28 |
Court | District Court, D. New Jersey | Date Terminated | 2018-11-27 |
Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
Jury Demand | None | Referred To | Leda Dunn Wettre |
Patents | 8,476,010 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in FRESENIUS KABI USA LLC v. BIOQ PHARMA INC.
Details for FRESENIUS KABI USA LLC v. BIOQ PHARMA INC. (D.N.J. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-02-28 | 1 | BACKGROUND The Patent-in-Suit: United States Patent No. 8,476,010 20. The ʼ010 patent, entitled… infringement of United States Patent No. 8,476,010 (“the ʼ010 patent”). This action arises out of BioQ…”). COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,476,010 BY BIOQ 28. The allegations …INFRINGEMENT OF U.S. PATENT NO. 8,476,010 BY BIOQ 38. The allegations …rights, title, and interest in the ʼ010 patent. The ʼ010 patent will expire on June 1, 2025. A true and | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |